Abstract. Conducting phase I trials is particularly challenging when dealing with late-onset dose-limiting toxicity (DLT) or when patient accrual is rapid relative to the DLT assessment window. In ...

Summary. Antibody–drug conjugates are an emerging treatment of non–small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic ...

Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...

The FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved BCMA- and CD19-targeting chimeric antigen receptor (CAR) T-cell therapies. The FDA can require a REMS ...

The American Society for Radiation Oncology (ASTRO) issued new guidance on using radiation therapy to treat grade 4 diffuse gliomas, which account for nearly half of malignant brain tumors in adults ...

AbstractPurpose:. Melanoma brain metastases (MBM) are common in advanced melanoma and linked to poor prognosis. Preventing MBM can improve survival and reduce morbidity. Although dual-agent ...

The FDA gave accelerated approval to datopotamab deruxtecan (Datroway; Daiichi Sankyo), a TROP-2 targeting antibody–drug conjugate (ADC), for patients with advanced or metastatic EGFR-mutated ...

Major Finding: An intraoperative sequencing workflow provides rapid turnaround of comprehensive molecular profiling of central nervous system (CNS) tumors. Concept: Methylation profile and DNA copy ...

Major Finding: Uptake of exogenous lipoproteins through glycosaminoglycans protects cancer cells from ferroptosis.Concept: Lipoproteins inhibit ferroptosis by delivering α-tocopherol, a form of ...

Adding pembrolizumab (Keytruda; Merck) to standard of care improved event-free survival for patients with head and neck squamous-cell carcinoma (HNSCC) in the phase III KEYNOTE-689 study, according to ...

First Disclosures First Disclosures in Molecular Cancer Therapeutics present drugs for the first time in published literature, accompanied by pertinent translational investigations. Submissions are ...

AbstractImmune checkpoint blockade (ICB) has revolutionized cancer treatment. Unfortunately, the inability of lymphocytes to infiltrate the tumor nest, a phenomenon known as immune exclusion, ...